Latest News and Press Releases
Want to stay updated on the latest news?
-
-- Company provides update on ZEMDRI® commercialization and launch -- -- Data from both the EPIC and CARE Phase 3 clinical studies of plazomicin are expected in peer-reviewed publication -- SOUTH...
-
-- Plazomicin may be well-suited to play a critical role in biodefense preparedness -- SOUTH SAN FRANCISCO, Calif., Feb. 14, 2019 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ: AKAO), a...
-
SOUTH SAN FRANCISCO, Calif., Dec. 10, 2018 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ: AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents...
-
SOUTH SAN FRANCISCO, Calif., Nov. 26, 2018 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ: AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents...
-
SOUTH SAN FRANCISCO, Calif., Nov. 09, 2018 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ: AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents...
-
-- Company provides update on ZEMDRITM commercialization and launch -- -- Conference call today at 8:30 a.m. Eastern Time -- SOUTH SAN FRANCISCO, Calif., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Achaogen,...
-
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ: AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents...
-
SOUTH SAN FRANCISCO, Calif., Nov. 02, 2018 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ: AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents...
-
Achaogen Submits Marketing Authorization Application to the European Medicines Agency for Plazomicin
-- MAA submission for complicated urinary tract infections (cUTI), bloodstream infections, and infections due to Enterobacteriaceae in adult patients with limited treatment options -- SOUTH SAN...
-
SOUTH SAN FRANCISCO, Calif., Oct. 03, 2018 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ: AKAO), a biopharmaceutical company discovering, developing, and commercializing innovative antibacterial agents...